Slide 1: OptiScan March 2019 Presentation
ASX Announcement 14 March 2019 OptiScan March 2019 Presentation Dear Shareholders, Optiscan Imaging Limited (ASX: OIL) is pleased to provide this presentation on the development of additional human applications for the use of Optiscan’s confocal laser endomicroscope technology. The presentation high
Slide 2: Optiscan Imaging Ltd
Optiscan Imaging Ltd (ASX:OIL) Diagnostic and Intraoperative Clinical Devices “Unlocking the Potential in Human Applications”
Slide 3: Disclaimer
Disclaimer This presentation has been prepared by Optiscan Imaging Limited (OIL). This presentation contains summary information about OIL which is current as at 14 March 2019. Neither the OIL, nor any of its officers, employees, officers, agents, consultants or advisers are under any obligation to
Slide 4: Disclaimer
Disclaimer Past performance The operating and historical financial information given in this presentation is given for illustrative purposes only and should not be relied upon as (and is not) an indication of OIL's views on its future performance or condition. Actual results could differ materially
Slide 5: Optiscan Imaging Ltd
Optiscan Imaging Ltd Developer and Manufacturer of Clinical and Translational EndoMicroscopes New Human Clinical Application Developments Product development and modifications to the FIVE2 (ViewnVivo) being undertaken to enable oral, cervical, breast and other human clinical applications. Prototyp
Slide 6: Clinical and Pre-Clinical Applications
Clinical and Pre-Clinical Applications CLINICAL PRE-CLINICAL APPLICATION STATUS APPLICATIONS APPLICATION BREAST CERVICAL ORAL OESAPHAGEAL NEURO PRE-CLINICAL Device Optiscan Rigid Optiscan Rigid Optiscan Rigid Flexible FIVE2 (ViewnVivo) Endomicroscope Endomicroscope Endomicroscope Endomicroscope* Ins
Slide 7: ASX Announcements
ASX Announcements Memorial Sloan Kettering Cancer ASX Announcement Centre (MSKCC) Announcement 26 February 2019 26 February 2019 OptiScan technology used in research at major cancer center Optiscan is pleased to announce that Memorial Sloan Kettering Cancer Center (MSK) in New York City is using Opt
Slide 8: PARPi-FL – Optical and Diagnostic Imaging Agent
PARPi-FL – Optical and Diagnostic Imaging Agent PARPi-FL A molecular based imaging agent Possesses unique pharmacokinetics properties for topical as well as intravenous injection Targeting PARP1, an enzyme that is highly overexpressed in several human cancers such as oral squamous cell carcino
Slide 9: What is PARP1 and PARP1 Inhibitors?
What is PARP1 and PARP1 Inhibitors? Poly(ADP-ribose) polymerase PARP1, is an enzyme in the cell nucleus which is activated by DNA damage acting as a ‘molecular nick sensor’ to signal DNA single-strand breaks (SSBs) and assist in their repair. It is significantly over expressed (high quantities) in c
Slide 10: Breast, Cervical, Oral and Oesophageal Cancer
Breast, Cervical, Oral and Oesophageal Cancer Estimated incidence of cancer types below with far higher number of potential diagnostic assessments * American Cancer Society Estimated 2019 Statistics. ** Cancer Statistics in China, 2015, published in CA: A Cancer Journal for Clinicians, researchers l
Slide 11: Opportunities for Improved Patient Outcomes with Optiscan CLE
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) BREAST CANCER 13% and 15% of all cancers in Australia and the United States respectively. “Best estimates suggest that 60–80% of women with early-stage breast cancer in Australia undergo breast-conservi
Slide 12: Assessment of Breast Cancer Surgical Margin
Assessment of Breast Cancer Surgical Margin 271,270 estimated new cases of invasive breast cancer diagnosed in the United States in 2019 and 18,235 new cases diagnosed in Australia in 2018. Nearing completion of Stage 1 of breast cancer surgical margin assessment trial. Imaging analysis of 42 ex
Slide 13: Opportunities for Improved Patient Outcomes with Optiscan CLE
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) ORAL CANCER Comprise 85% of head and neck cancers (excluding brain cancers). Worldwide, there are over 450,000 new cases each year. 1 53,000 Americans will be diagnosed with oral or oropharyngeal cancer
Slide 14: Opportunities for Improved Patient Outcomes with Optiscan CLE
Opportunities for Improved Patient Outcomes with Optiscan Confocal Laser Endomicroscopy (CLE) CERVICAL CANCER Cervical cancer is the fourth most common cancer among women globally. In Australia, there were 930 new cases in 2018 and 258 deaths and in the USA for 2019 it is estimated to be 13,170 ne
Slide 15: Cervix – CLE and Histopathology Correlation
Cervix – CLE and Histopathology Correlation “The majority of the decline in invasive cervical cancer rates in developed countries is due to a reduction in squamous cell carcinoma. In contrast, the incidence of adenocarcinomas has not declined, largely attributed to difficulties in detecting these ty
Slide 16: Sterilizable Probe Sheath
Sterilizable Probe Sheath Design of Optiscan’s sterilizable sheath completed. Third party validation testing to be undertaken in the near term.
Slide 17: Carl Zeiss Meditec (CZM) Collaboration
Carl Zeiss Meditec (CZM) Collaboration FDA510(k) and CE Mark for CZM Convivo CZM advises commercialisation progressing in neurosurgery Belykh E, Cavallo C, Gandhi S, Zhao X, Veljanoski D, Izady Yazdanabadi M, et al. Utilization of intraoperative confocal laser endomicroscopy in brain tumor surge
Slide 18: Translational and Pre-Clinical Research
Translational and Pre-Clinical Research Increased profile in Australian translational and pre-clinical research markets. Multi-faceted re-branding of FIVE2 (ViewnVivo) including new website in late 2018. Conducted workshop at Light Microscopy Association conference in Brisbane, March 2019 and
Slide 19: Summary and Future Outlook
Summary and Future Outlook A strategic transformation of Optiscan has taken place over the last 10 months. Optiscan CLE is being enabled for intraoperative and diagnostic use in the operating theatre, medical and dental clinic and pathology laboratory. Human applications of CLE have grown from